[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641384":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Distributive shock patients undergoing norepinephrine dose reduction",null,"Mechanically ventilated distributive shock patients in whom the attending physician clinically indicated norepinephrine dose reduction, with MAP transitioning from the 75-85 mmHg range to the 65-75 mmHg range.",[13],"Other: Not applicable- observational study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Not applicable- observational study","Observation of hemodynamic parameters before and after clinically indicated norepinephrine dose reduction. No investigator-initiated intervention was performed.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Bin Du, Dr","CONTACT","86+15136289398","sunyaliii@163.com",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40],{"name":41,"role":22,"phone":42,"phoneExt":10,"email":24},"Bin Du","86-15136289398",{"type":44,"investigatorFullName":41,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Professor","100641384","hemodynamic-effects-of-norepinephrine-reduction-on-critical-closing-pressure-in-distributive-shock-100641384",false,"NCT07653659","Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock","Changes in Critical Closing Pressure and Derived Hemodynamic Parameters Following Norepinephrine Dose Reduction in Distributive Shock Patients: a Prospective Observational Study","Inclusion Criteria:\n\n1. Adult distributive shock patients aged ≥18 years;\n2. Receiving norepinephrine infusion with MAP in the 75-85 mmHg range;\n3. PiCCO catheter in situ;\n4. Under mechanical ventilation;\n5. Clinically indicated norepinephrine dose reduction per attending physician judgment.\n\nExclusion Criteria:\n\n1. Significant cardiac arrhythmia affecting CO measurement reliability;\n2. Contraindication to airway plateau pressure maneuver;\n3. Active titration of other vasoactive agents within 30 minutes prior to measurement;\n4. Hemodynamic instability making it impossible to reduce norepinephrine dose.","ALL","18 Years",{"count":56,"type":57},30,"ESTIMATED","OBSERVATIONAL","This study prospectively observes changes in critical closing pressure (Pcc) and derived hemodynamic parameters in mechanically ventilated distributive shock patients when clinically indicated norepinephrine dose reduction is performed by the attending physician. Pcc is measured before and 30 minutes after dose reduction using a stepwise inspiratory hold maneuver via PiCCO monitoring.",[61,62,63],"Distributive Shock","Hemodynamic Assessment","Critical Illness",[65,66,67,68,69],"Critical closing pressure","Tissue perfusion pressure","Vascular waterfall","Norepinephrine dose","Distributive shock","2026-06-12",{"date":72,"type":73},"2026-06-17","ACTUAL",{"date":75,"type":73},"2025-09-01",{"date":77,"type":57},"2027-09-01",{"name":5,"class":6},1]